Ponatinib is a potent multi-targeted PTK inhibitor and is a very useful and critical agent for chronic myeloid leukemia (CML) and philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), particularly those with T315I mutations. Here, PTK2B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.